Teaching Philosophy and Approach - University of … Hartford Hospital Department of Pharmacy Core...

Teaching Portfolio C. Michael White, Pharm.D., FCP, FCCP

Professor and Head

Department of Pharmacy Practice

University of Connecticut

02/02/12

Table of Contents:

Section

1. Teaching Responsibilities A

2. Teaching Philosophy and Approach B

3. Teaching Goals and Awards C

4. Formal Letters of Teaching Assessment D

5. Student Didactic Teaching Assessment E

6. Student Experiential Teaching Assessment F

7. Non-Research Symposia/CE Programs G

8. Research Evaluating my Teaching H

10. Book Chapters and Review Articles of Note I

Teaching Responsibilities Section A

C. Michael White, Pharm.D., FCP, FCCP

Professor of Pharmacy


TEACHING EXPERIENCE

Student/Resident

Precepting

Jan 1996 – Present

Precepted Undergraduate (UConn, Albany College of Pharmacy) and PharmD students

(UConn, SUNY Buffalo, Creighton, Ohio Northern, Mass College of Pharmacy) (n>300).

July 1998 – Present

Precepted Pharmacy Practice Residents (Hartford Hospital, Connecticut VAMC) (n=18).

Graduate Fellows August 1998 – July

1999 Interim Director of the Outcomes Research Fellowship at Hartford Hospital

Graduated Fellow: Prabashni Reddy, Pharm.D.

July 2002-June 2003

Interim Director of the Outcomes Research Fellowship at Hartford Hospital

Graduated Fellow: Craig Coleman, Pharm.D.

August 1998 – June 2006

Director of the Cardiovascular Outcomes Fellowship at Hartford Hospital

Graduated Fellows:

Alisha Dunn, Pharm.D. June 1999, Medical Science Liason Manager, Scios

Pharmaceuticals

James Tsikouris Pharm.D. June 2000, Currently Assoc Prof, University of

Pittsburgh

Jessica Song, Pharm.D. June 2001, Currently Assoc Prof, Univ of the Pacific

Michael Caron, Pharm.D. June 2002, Currently Medical Science Liason, Canyon

Pharmaceuticals

James Kalus, Pharm.D. June 2003, Currently Assoc Director, Henry Ford Hospital

Brian McBride Pharm.D., June 2004, Currently Asst Prof, Loyola University

Bokyung Min, Pharm.D. July 2005, Currently Asst Prof, Nova Southeastern.

Stephen Sander, Pharm.D. March 2006, Currently Manager, Outcomes Researcher,

Boringer-Ingelheim Pharmaceuticals,

Nickole Henyan, Pharm.D. June 2006, Currently Clinical Specialist, Shore Health

System

Krista Dale, Pharm.D. June 2007, Currently Clin Spec, Mississippi Medical Center

Sachin Shah, Pharm.D. June 2007, Currently Asst Prof, Univ of the Pacific

William L Baker, Pharm.D., BCPS., Currently Asst Prof, UCONN

Kurt Reinhart, Pharm.D., Currently Asst Prof. Wingate University.

Ripple Talati, Pharm.D., Senior Scientist, UCONN/HH EPC

Olivia Phung, Pharm.D., Currently Asst Prof, Western University

June 2006 – Present

Co-Director of the Cardiac Outcomes Fellowship at Hartford Hospital

Current Fellows: Jennifer Colby, Pharm.D., Wendy Chen, Pharm.D.,

Jennifer Scholle, Pharm.D., Soyon Lee, Pharm.D.

Visiting

Scholars/Pharm.D.

Students

Feb 1999 - Sept

1999

Preceptor of Two Visiting Scholars (MDs) in Cardiovascular Pharmacology, Hartford, CT

Graduated Scholars: Jianlin Xie, MD, Yianling Sun, MD (September 1999)

Feb 2002 – Apr 2003 Preceptor of Visiting Scholar (Pharmacist) in Cardiovascular Pharmacology, Hartford, CT

Graduated Scholar: Liu Xing, MS Pharmacy.

Apr 2008 Preceptor of Two French Students from the University de Rennes, Hartford, CT

French Students: Anais Le Rhun, Elodie E Raider

Apr 2010 Preceptor of Two French Students from the University of Rennes, Hartford, CT

French Students: Anne-AmélieCuris, Nadege Seznec.

Jul 2010 Preceptor of Student from University of Puerto Rico, Hartford, CT

Student: Nahir Rivera

Student Research

1999-Present Preceptor of Undergraduate Research Students, UConn School of Pharmacy, Storrs, CT

Graduated with Honors: Rabab Ammar, Pharm.D. (2 Semesters, May 2001).

Agnes Krudysz Pharm.D. & Angie Karapanos Pharm.D. (2 Semesters + 1 Rotation Month, May

2004). Pauline Rafferty (May 2005)

Graduated with Distinction: Audrea Hotsko Pharm.D. & Stacey Robertson, Pharm.D. (2 Semesters +

1 Research Month, May 2002), Alexandria Piotrowski, Pharm.D. (2 Semesters + 1 Research Month,

May 2003), Deborah Cios, (4 Semesters, September 2004-May 2007)

Graduated Students: Jenny Chung, Pharm.D. (February 2002), William Baker, Pharm.D. (March

2002), Audrea Hotsko, Pharm.D. and Steven Sander, Pharm.D. (April 2002), Heather Sun, Pharm.D.

and Nick Hawryz, Pharm.D. (April 2003), Christopher Fortier, Pharm.D., Vinnita Sinha, Pharm.D.

(April 2004), Michael Kardas, Pharm.D.& Agron Ismaili, Pharm.D. (2 Semesters Ending + 1 rotation

ending June 2004), Jade Pham, Pharm.D. (July 2004), Jasmine Sahni, Pharm.D. (January 2005), Sean

Norton (July 2005), Elizabeth Lucina (April 2006), Aaron Hussey (June 2006), Jennifer Morrone

(August 2006), Eang Lao (October 2006), Jenny Lipieki (3 semesters January 2005-May 2007),

Payal Vachhani (Two semesters, 2007-2008, HONORS), Colleen J Teevan (January 2007-2010,

HONORS), Lauren Tuttle (Two Semesters, 2008-2010 HONORS)

Current Research Students: Agata Dabek (P3), Katarzyna Zlotnik (P3),

Preceptor of Research Training Experience, St Joseph’s College, Hartford, CT

Graduated Student: Lilia Mandybur (2 Semesters Ending August/December 2001)

UConn Didactic

Courses

Undergraduate

1997-1998 Pharmacokinetics (Pharmacy 230). Lecturer on Antiarrhythmic Drug

Pharmacokinetics

1998-1999 Cardiovascular Therapeutics Module (Pharmacy 280). Lectures on

Angina/Myocardial Infarction, Hypertension, Thromboembolism, Arrhythmias,

Congestive Heart Failure

1998-1999 Pharmacy Research Seminar (Pharmacy 201) for Honors Program Students.

Lecturer on Research

Pharm.D. Program

1998-Present Pharmaceutical Care (PHRM 207). On-Site Lecturer

1998-Present Cardiology Therapeutics Module (PHRM 254). Lectures on Hyperlipidemia,

Angina, Myocardial Infarction, Arrhythmias, Congestive Heart Failure

2003-Present Cardiology Therapeutics Module (PHRM 254). Lecture on Cardiovascular Drugs

Pharmacokinetics

2005-2006 Cardiology Therapeutics Module (Phrm 254): Lecture on Hypertension and

Interpreting Acid-Base Disorders.

1999-2009 Literature Evaluation and Biostatistics (PHRM 200/PHRX 3000). Course Co-

Coordinator and Lecturer.

1999-2002 Clinical Pharmacokinetics (PHRM 257). Lecturer on Antiarrhythmic Agents

Pharmacokinetics

1999-2000 Pharmacy Research Seminar (PHRM 201) for Honors Program Students. Lecturer

on Research

1999-2005 Physical Assessment Course (PHRM 211). Lecturer (ECG Skills/Heart Sounds),

Laboratory Instructor (CV exam plus GI exam).

2001-2003 Nonprescription Medication Course (PHRM 210). Lecture on Head & Body Lice.

2003 – Present Nonprescription Medication Course (PHRM 210). Lecture on Herbs With Cardiac

Implications.

2006 – 2007 Drug Induced Diseases (PHRM 258W). Lecture on Drug Induced Cardiac Disease

and Preceptor of Major Student Writing Projects

2008 – 2009 Pharmacy Honors Seminar (Phar 201). Lecture on Research Aimed to Prevent Drug

or Surgery Induced Diseases.

2008 – Present Evidence-Based Practice (PHRX 3095, ELECTIVE). Lectures on Evidence Based

Practice and Use of Systematic Review to Discern that Evidence.

2009-2010 Pharmacy Honors Seminar (Phar 201). Lecture on Research Related to Evience-

based Practice.

2009 – Present Drug Information II (PHRX3007). Lectures on Interpreting Primary Literature and

Statistical Analysis.

Masters in Clinical

Translational

Research

2008-2010 Core III: Evidence Based Practice. Lectures on Evidence-Based Practice and Use of

Meta-Analaysis/Systematic Review to Discern Evidence. UCHC, Farmington, CT.

Hartford Hospital

Didactic Courses

1996-2002 Advanced Practice Registered Nurse Certification Program (APRN). Lecturer on

Cardiovascular Therapeutics

1996-2003 Advanced Cardiac Life Support Certification Program (ACLS). Pharmacology

Lecturer.*

* - Awarded Best ACLS Teaching Program in New England 1999.

2001-Present Hartford Hospital Department of Pharmacy Core Competencies Lecture Series. Lectures on

Myocardial Infarction, Congestive Heart Failure, Hyperlipidemia, and Arrhythmias

Completed Annually and Video Taped. Video Tapes are Mandatory for New Pharmacist

Orientation Period.

2001-2009 University of Connecticut School of Medicine Medical Intern and Resident Pharmacology

Lectures at Hartford Hospital. Lectures on Myocardial Infarction, Congestive Heart Failure,

Hyperlipidemia, and Arrhythmias Completed Annually.

2002-2009 Hartford Hospital Division of Cardiology Fellow Lecture Series. Annual Lectures on

Research Within our Group and Treatment of Hypertension.

2003-2007 Coordinator of Advanced Cardiac Life Support Certification Pharmacology Lectures.

Teaching Philosophy and Approach Section B




“Some people talk in their sleep. Lecturers talk while other people sleep.”

– Albert Camus

The pharmacy profession entrusts me to train competent and compassionate future

pharmacists and to continue the training of current pharmacists. Pharmacists of

yesteryear such as Albert White and Henry Palmer have demonstrated to me through

their actions what an awesome responsibility that is. Their love and dedication for their

profession was passed down to me and I have a responsibility to pharmacists of the past

like them and to the pharmacists of tomorrow to bestow drug knowledge while also

instilling a sense of pride in the profession and a real personal concern for patient care.

As such, I believe that I need to be a teacher, facilitator, and leader. The important tenets

of didactic and experiential teaching to which I ascribe are delineated below.

As you read the tenets of my pedagogical approach, I hope you will appreciate that I did

not just stumble upon this philosophy and approach. I started with a strong baseline

teaching approach (emulated from the professors that impacted me such as Ronald Gailey

and Robert Hamilton) and then continued to refine it over the years. Discussions with

other instructors, reading books on leadership and teaching, and through self assessment I

have identified some weaknesses and attempted to correct them by trying some new

things. However, the biggest changes in my teaching have arisen from discussion that I

have had with the students about what instructors they love, what they love about them,

what are the things that I do well, and what I could do to improve my pedagogy. This

open exchange of ideas has been the primary driver of teaching improvement. Based on

this feedback and self-assessment I developed Pharmacist Interactive Clinical Cases

(PICCs). This learning platform seems especially well suited to demonstrating the use of

drug knowledge in the simulated care of the patient. With this case approach, I have first

used study methodology to evaluate instructional effectiveness. Overall, the PICCs cases

rated much higher amongst pharmacy students than standard case based teaching formats.

Didactic Teaching: I believe that there are 5 qualities that a teacher needs to have to

underpin optimal didactic pedagogy. I have tried to incorporate these in my teaching

wherever possible.

1. Pragmatic: To use the time allocated in a manner that optimizes the learning

experience. By starting with the time allocated to a certain topic and then

devising a the lecture content, I can determine the most important topics to be

covered and allow time to enrich the content with examples and cases,

empowering the students to learn and to utilize the information in their

professional lives, and to prevent boredom that sucks out student’s life force over

the course of the class period. I think that teachers get into trouble when they are

given a topic and think that it is a mandate that they need to cover 5 hours of

material in 3 hours. This stifles creativity, creates frustration amongst students,

and prevents optimal student learning.

2. Enriching: To provide not only the content but to provide context. Context is

important because it helps students see how the knowledge can be learned,

understood, and used in their professional lives. A Chinese Proverb states a

learning philosophy: “Tell me and I will forget, show me and I may remember,

involve me and I will understand.”

3. Empowering: Even if students understand a concept and know how it can be used

in patient care, that doesn’t assure that they will use that information in that

manner in their professional lives. Students, like most everyone, need to be

inspired to act for the betterment of their patients. To create a caring health

professional, real life examples of medical care gone wrong due to a lack of

involvement and the impact of a health professional on a patient’s life really does

motivate students in a positive way.

4. Not Boring: The best content and the snappiest slides will not achieve optimal

knowledge attainment if the students are bored. The use of enrichment to help

understanding and involvement of the students in the learning process as well as

empowering students are important techniques to stave off boredom. However,

the use of humor dispersed sparingly throughout the class period that is loosely or

integrally related to the topic material not only stimulates interest but also makes

the faculty person seem more approachable and human. If done too much, it can

causes a loss of student focus and distracts from learning.

5. In Control: While some measure of lightheartedness in class is valuable and

student perception that it is ok to ask questions is valuable, the majority of

students should not be disadvantaged from learning due to disruptive students.

Acceptable student conduct needs to be explicitly spelled out and the faculty

member needs to assure that a single student does not have the capacity to derail

the learning of the majority. I am sure that at this point most people reading this

are thinking about the poorer quality student or the class clown and do occur.

However, advanced or truly gifted students can also derail learning by incessantly

asking questions that while delivered at a high level and are not relevant to vast

majority of students. In both circumstances, the faculty person needs to

communicate with the student out of class and explain what the concern is and

how to remedy it. For example, the advanced students should know that you

would be happy to answer these questions out of class and would enjoy the

discussion but the problem associated with having a two person conversation in

front of a class of 100 students given dense learning content.

Experiential Teaching: Similarly, I believe that an optimal experiential rotation is

underpinned by 4 main qualities. I try to incorporate these qualities into my experiential

rotations every month.

1. Assuring: Students need to achieve a standard level of clinical knowledge before

initiating patient contact. I believe that students should be intensively trained and

their knowledge assessed for the first 2 days of the rotation before they are

allowed to start interacting with other health professionals. A third day can be

added if needed. If students do not have adequate baseline knowledge, they have

nothing to contribute to the healthcare team initially. This means that they run the

risk of being made an outsider for the entire month even when they catch on and

have something to contribute. By assuring the healthcare team that only well

trained students are on rounds, members of the healthcare team are more likely to

incorporate students into the team earlier and more fully so students can have the

optimal experience.

2. Empowering: Making students go into the patient’s room and introduce

themselves and let the patient and their family know they will be looking at the

patient’s drugs to prevent drug interaction, assure optimal dosing, and to help in

drug selection is a wonderful technique to help students accept ownership for the

patient’s health. In afternoon discussions, reinforcing that the patients they are

presenting are real people and that they are in need of good pharmaceutical care to

help the student accept personal responsibility for the patient. If a student can see

the patient as a person rather than a case or a project than you do not have to

motivate them, just guide them.

3. Facilitative: Students need to be able to practice their craft. If their rotation

preceptor is with them all the time and is taking the lead, the student does not get

to feel the responsibility for direct patient care. They know that their responses

will be filtered through another person which waters down their experience. By

having students meet intensively early on to assess knowledge competency,

shadowing the students on rounds for the first 5 rounding days (more if needed),

and then giving them the freedom to round on their own for the rest of the rotation

seems to be a good approach. By meeting daily to discuss all patients before the

end of the day, students can discuss their patients and try out their potential

interventions to see if they should be made before going on rounds. I call this

process facilitative independence.

4. Intense to the End: The end of a rotation can create a lull in learning and growth.

The students can extract chart information with greater ease, they know what is

expected with patient presentations during preceptor discussions, and they see the

end of the rotation coming. Over the course of the month, students have been

exposed to new drugs, new knowledge about these drugs, and new approaches to

treating patients but there needs to be an impetus for students to take this

knowledge and incorporate it into their long term memory. Only then can the

knowledge be applied to future patients. Incorporating an end of rotation oral

final exam that focused on the drug knowledge that should have been attained

helps meet the aforementioned goals. Having students deliver a high quality

formal presentation to the faculty on site, residents, and fellows also help students

develop confidence in their ability to teach and enhances their drug knowledge.

By scheduling the presentations towards the end of the rotation, students have an

activity to work at that can also help prevent the end of rotation lull.

Teaching Goals and Awards Section C




Short Term Goals: 1. Revise lectures for my current courses to continue to provide updated and

clinically relevant lecture material.

2. Enhance Pharmacist Interactive Clinical Cases (PICCs) to encompass more

physical assessment.

3. Design 1 additional PICC for additional educational content.

Long Term Goal:

1. Advance the use of active learning and integration of knowledge across modules

through an additional focus on PICCs in my portion of the new curriculum.

2. Maintain a highly effective advanced pharmacy practice experience rotation in the

face of mounting demands on my time as department head.

Teaching Awards:

March 2001 Teacher of the Year, University of Connecticut School of Pharmacy, Storrs, CT.

March 2004 Teacher of the Year, University of Connecticut School of Pharmacy, Storrs, CT.

April 2006 Teaching Fellow Designation Awarded. University of Connecticut. Highest University

Teaching Award. Storrs, CT.

June 19, 2006 Hartford Courant: Featured in Article Entitled “Professor’s Comic Touches Help Students

Learn” for a Statewide Newspaper. Hartford, CT

The School of Pharmacy graduating class nominates the Teacher of the Year while

the University of Teaching and Learning at the University of Connecticut Designate

Teaching Fellows.

Formal Letters of Teaching Assessment Section D




Faculty Letters Include:

1. Alex Cardoni Formal Teaching Evaluation, March 2000

2. Rafaat Seifeldin, Pharm.D., PhD Teaching Fellow Award Nomination Letter,

February 2005.

3. Robert McCarthy, PhD, Teaching Fellow Award Nomination Letter, February

2005.

4. Robert McCarthy, PhD, Teaching Fellow Award Nomination Letter, February

2006.

5. Craig Coleman, Pharm.D., Teaching Fellow Award Nomination Letter, February

2005.

6. Jennifer Ellis, Pharm.D., Teaching Fellow Award Nomination Letter, February

2005.

7. Marla Campbell, Pharm.D., Teaching Fellow Award Nomination Letter, February

2005.

8. Philip Hritcko, Pharm.D., Teaching Fellow Award Nomination Letter, February

2006.

9. Michael Gerald, PhD, Teaching Fellow Award Nomination Letter, February

2006.

10. Michael Gerald, PhD, Evaluation Letter on my Lecture in “Careers in Pharmacy”

Course. January 2005.

11. American College of Clinical Pharmacy Review of Research Fellowship Training

Program. July 2001.

Student Letters Include:

1. Michael Kardas, Teaching Fellow Award Nomination Letter, February 2005.

2. Pauline Rafferty. Teaching Fellow Award Nomination Letter, February 2005.

3. Iwona Zalewska. Teaching Fellow Award Nomination Letter, February 2005.

4. Debarah Cios and Jennifer Lipeika. Teaching Fellow Award Nomination Letter,

February 2006.

5. Wanchen Tsao. Teaching Fellow Award Nomination Letter, February 2006.

6. Agron Ismaili. Teaching Fellow Award Nomination Letter, February 2005

7. Misc Cards from Past Students.

Student Evaluations of Teaching Section E




02.07.11

Student Evaluations of Teaching are given for every course where a faculty member

teaches more than 6 hours of content and are on a 10 point scale with higher scores

associated with better perception of teaching. For every course evaluated, my Student

Evaluation of Teaching Scores were above the departmental average, except one. In the

one instance where my SET score was at the average (Spring 2009), this was the only

time my name was hand written on the SET form, not mechanically imprinted. I am not

sure if the form was ascribed to me in error. My average score over all years is

9.300.45 versus the departmental average of 8.310.43, p<0.0001.

Year Dr White SET Scores

Dept Avg Scores Course Type

1998 Fall 9.6 7.1 Therapeutics

1999 Fall 9.7 7.8 Drug Lit Eval

2001 Spring 8.9 7.9 Therapeutics




2004 Spring 9.4 8 Therapeutics


2005 Spring 9.5 8 Therapeutics






Spring 2008 9.6 8.5 Therapeutics


2008 Fall 9.2 9 Evidence Based Practice


2009 Spring 7.8 7.8 Drug Info II


2010 Spring 8.7 8.2 Evidence-based Practice

2010 Fall 9.6 8.7 Cardiac Module

2010 Fall 9.8 8.9 Evidence-based Practice

2011 Spring 8.9 8.2 Drug Info II

Fall 2011 9.9 8.9 Evidence-based Practice

Fall 2011 9.3 8.6 Cardiac Module

Spring 2012 8.5 8.4 Drug Info II

Student Evaluations of Precepting Section F




Student Evaluations of Precepting (SEP) scores are the average score on a scale of 0-5

points from students on experiential rotations (Advanced Practice Pharmacy

Experiences). Of the 16 years where I had SEP scores, my SEP scores fell below the

departmental average in two of the years (2006 and 2007). At that time I became the

Director of the UCONN/Hartford Hospital EPC and increased scholarly time to 70-80%

(from 40% previously) with no reduction in the number of students I took. I needed to

dramatically reduce the time I spent with rotational students and utilize my research

fellows in a more substantive way, which took a few months (spanning two academic

years) to figure out. I am very pleased that since that time, I have created the right

experience and am again providing an above average experience. Since 2006 I am only

doing half of the normal rotational teaching and half the credit goes to the fellows that co-

precept these experiences.

Dr White SEP Scores

Dept Avg Scores

1996 4.87 4.3

1997 4.93 4.5

1998 4.75 4.4

2000 4.56 4.5

2001 4.93 4.3

2002 4.73 4.2

2003 4.92 4.4

2004 4.6 4.45

2005 4.84 4.72

2006 4.36 4.58

2007 4.06 4.62

2008 4.9 4.7

2009 4.75 4.7

2010 4.8 4.58

2011 4.85 4.56 2012 4.87 4.74

Non-Research Symposia/CE Programs

Section G C. Michael White, Pharm.D., FCP, FCCP



To date, I have delivered over 250 non-research lectures to Physicians, Pharmacists, and

Nurses. I have given medical and cardiology grand rounds and at both American Society

of Health System Pharmacists and American College of Clinical Pharmacy meetings. A

listing of the most important presentations I have delivered are summarized below.

Evaluations of these presentations have been exemplary but only a sample of these

evaluations are included.

NON-RESEARCH PRESENTATION

Selected From Over 250 Sponsored Lectures:

Oct 10, 1995 Drug Induced Respiratory Diseases: Focus on Apnea and

Bronchoconstriction.

Pharmacy Practice Institute: CE Program: Pharmacists: Albany, NY

Sept 30, 1996 Adverse Drug Reactions and Drug Interactions of Cardiovascular

Drugs Continuing Professional Education Service: CE Program: Pharmacists:

Wethersfield, CT

July 24, 1997 Recent Advances in Heart Failure Connecticut Pharmacists Association: CE Program: Pharmacists: Rocky Hill, CT

Nov 15, 1997 Understanding the Pathophysiology and Pharmacotherapy of

Depression Continuing Professional Education Service: CE Program: Pharmacists:

Wethersfield, CT

Apr 4, 1998 A Review of the Pharmacologic, Pharmacokinetic, and Therapeutic

Differences of HMG CoA Reductase Inhibitors.

Cardiology Noon Conference: St. Francis Hospital. Cardiologists, Medical

Residents: Hartford, CT

Apr 7, 1998 The Role of Catecholamines and Their Blockade in Heart Failure Connecticut Managed Care Consortium: Managed Care Pharmacists, Disease Case

Managers: Rocky Hill, CT

Jul 15, 1998 A Comprehensive Review of HMG CoA Reductase Inhibitors for Community

Pharmacists.

Western Massachusetts Pharmacy Conference: CE Program: Community

Pharmacists: West Springfield, MA

Aug 18, 1998 HMG CoA Reductase Inhibitors: An Evolving class.

CE Program: Clinical Pharmacists, Managed Care Pharmacists, Avon, CT

Jan 25, 1999 The Extrahepatic Pharmacological Effects of HMG CoA Reductase

Inhibitors Medical Grand Rounds, Berkshire Medical Center, Berkshire, MA

June 10, 1999 The Pharmacologic and Pharmacokinetic Effects of HMG CoA

Reductase Inhibitors New York State Pharmacist’s Association. CE Program: Poughkeepsie, NY

June 28, 1999 Cytochrome P450 Drug Interactions with HMG CoA Reductase

Inhibitors Albany Veterans Administration Medical Center: Albany, NY

Sept 9, 1999 An Update on the Therapeutic Management of Heart Failure Patients Kentucky Society of Health-System Pharmacists: CE Program: Lexington, KY

Dec 4, 1999 Pharmacologic and Pharmacokinetic Comparison of ACE Inhibitors Post-

Myocardial Infarction

ASHP Midyear Meeting: Consensus Conference: Orlando, FL

Jan 20, 2000 A Review of CYP 3A4 Drug Interactions for the Pharmacist.

Mid-Hudson New York State Pharmacy Council: CE Program: Newburgh, NY

Mar 10, 2000 ACEIs in the Treatment of CHF/Post-MI Sequelae.

California Society of Health-System Pharmacists: CE Program: Oakland, CA

Mar 10, 2000 ACEIs: A Rationale for Formulary Decisions.

California Society of Health-System Pharmacists: CE Program: Oakland CA

Mar 16, 2000 Evaluating the Drug Literature: Tips for Primary Care Professionals Continuing Education Grand Rounds: The Institute of Living: Hartford, CT

Mar 21, 2000 A Review of the Pharmacologic and Pharmacokinetic Differences of HMG

CoA Reductase Inhibitors

Connecticut Society of Health-System Pharmacists March Meeting: CE program:

Farmington, CT

May 25, 2000 A Review of the Pharmacologic Differences of HMG CoA Reductase

Inhibitors Greater Bridgeport Pharmacy Council Meeting: CE Program: Bridgeport, CT

May 28, 2000 The Use of Intravenous Amiodarone in the Cardiac Arrest Patient.

Wyndham Hospital Quarterly Emergency Department Meeting: EMTs, ED

Physicians and Nurses: Wyndham, CT

Jun 24, 2000 Drug Interactions Between Cardiovascular Drugs and Over the Counter or

Herbal Products.

Connecticut/Mid-Hudson NY VNA Annual Meeting: CE Program: Newtown, CT

Aug 25, 2000 Review and Comparison of Thrombolytic Agents.

Eastern Conference Health Network Pharmacists, Nurses, ED Physicians:

Manchester Memorial Hospital: Manchester, CT.

Sept 19, 2000 A Pharmacokinetic and Safety Comparison of HMG CoA RIs.

CE Program: Pharmacists: Norwalk, CT.

Oct 25, 2000 A Pharmacokinetic and Safety Comparison of HMG CoA RIs.

CE Program: Physicians: Rye Brook, NY.

Oct 27, 2000 A Review of Thrombolysis in Acute Myocardial Infarction for Hospital

Pharmacists.

CE Program: Pharmacists: CSHP Catch the Wave Meeting: Meridan, CT

January 5, 2001 An Update on Research in the Arrhythmia and Cardiovascular Pharmacology

Group.

Cardiology Noon Conference: Cardiologists: Hartford Hospital, Hartford, CT

January 18, 2001 A Review of Pregnancy Drug Guidelines and Pregnancy Categories.

Internal Medicine Morning Conference: Internists: Hartford Hospital, Hartford, CT

April 10, 2001 An Update on the Pharmacotherapy of Acute Myocardial Infarction.

CE Program: Pharmacists, Hartford Hospital, Hartford, CT

April 17, 2001 An Update on the Pharmacotherapy of Congestive Heart Failure.

CE Program: Pharmacists, Hartford Hospital, Hartford, CT

April 24, 2001 Moderator: Therapeutic Debates on (1) Implantable Defibrillators Versus

Antiarrhythmics and (2) Use of Abciximab as First Line Therapy in PCI.

CE Program: American College of Clinical Pharmacists Meeting. Salt Lake City,

Utah

December 3, 2001 Moderator: A Review of Critical Differences Between Drugs Within Common

Cardiovascular Drug Classes.

CE Program: Midyear Clinical Meeting of the American Society of Health-

Systems Pharmacists. New Orleans, LA

December 3, 2001 A Review of Critical Differences Between HMG CoA RIs.


Systems Pharmacists. New Orleans, LA

December 4, 2001 QTc Prolongation, How Much is Too Much? CE Program: Part of the Cardiovascular Implications of Atypical Antipsychotics.

American Society of Health-Systems Pharmacists Dinner Program. New Orleans,

LA

December 11, 2001 Intravenous Amiodarone in Sustained Ventricular Tachyarrhythmias.

CE Program: Registered Nurses, APRNs: Education Resource Center, Hartford,

CT.

January 18, 2002 QTc Prolongation: How Much is Too Much? Psychopharmacology Grand Rounds, CE Program: Psychiatrists, Psychiatric

Pharmacists, Nurses: Institute of Living, Hartford, CT.

February 14, 2002 An Update on New Pharmacologic Agents for Advanced Cardiac Life

Support

Physicians, Registered Nurses: Franklin Square Hospital, Baltimore, MD.

March 21, 2002 An Update on New Pharmacologic Agents for Advanced Cardiac Life

Support

Pharmacists, Registered Nurses: Physicians Community Hospital, Lanham, MD.

March 27, 2002 QTc Prolongation: How Much is Too Much? Pharmacists, Nurses, Psychiatrists, Capital Region Mental Heath Facility.

Hartford, CT.

April 25, 2002 An Update on New Pharmacologic Agents for Advanced Cardiac Life

Support Registered Nurses, Physicians, Hartford, CT

May 2, 2002 QTc Prolongation: How Much is Too Much? Physicians. Department of Psychiatry. Baystate Medical Center. Springfield, MA.

May 14, 2002 QTc Prolongation: How Much is Too Much? Psychiatrists, Psychiatric Nurses, Institute of Living, Hartford, CT.

Jun 24, 2002 QTc Prolongation: How Much is Too Much?

Psychiatrist’s Monthly Meeting, Institute of Living, Hartford, CT. July 10, 2002 An Update on New Pharmacologic Agents for Advanced Cardiac Life

Support

Pharmacists. Bristol Hospital, Bristol, CT. July 17, 2002 An Update on New Pharmacologic Agents for Advanced Cardiac Life

Support

Emergency Room, Critical Care Personnel. Waterbury Hospital, Waterbury,

CT. July 22, 2002 The Pharmacologic Management of Heart Failure.

Pharmacists, Cardiac Nurses. New Britain General Hospital, New Britain,

CT.

July 24, 2002 An Update on New Pharmacologic Agents for Advanced Cardiac Life

Support Emergency Department Grand Rounds: Emergency Department Physicians. Sinai

Hospital, Baltimore, MD.

August 6, 2002 Administration of PPIs in patients Who Cannot Swallow.

Pharmacy Department. Baystate Medical Center. Springfield, MA.

October 7, 2002 Administration of Proton Pump Inhibitors through Nasogastric Tubes.

Teleconference: Eastern Medical Science Liasons. AstraZeneca Pharmaceuticals.

October 9, 2002 Administration of Proton Pump Inhibitors through Nasogastric Tubes.

Teleconference: Western Seaboard Medical Science Liasons. AstraZeneca

Pharmaceuticals.

October 17, 2002 New Choices for the Cardiac Patient.

CE Program: American Heart Association. Connecticut Society for Cardiac

Rehabilitation: Nurse Practitioners, Physician Assistants, Allied Health:

Wallingford, CT

November 10, 2002 Racial Differences in Heart Failure Pharmacotherapy.

CE Program: American College of Clinical Pharmacists. Salt Lake City, Utah.

November 19, 2002 Statin Induced Muscle Toxicity: Impact of Pharmacology and

Pharmacokinetics.

CE Program: CVS Pharmacy: Community Pharmacists: Danbury, CT

December 9, 2002 Moderator: Critical Differences of Cardiovascular Drugs II CE Program: Midyear Clinical Meeting of the American Society of Health-

Systems Pharmacists. Atlanta, GA

December 9, 2002 Critical Differences Between Beta-Blockers.



December 10, 2002 Moderator: New Drugs with Patient Care Impact CE Program: Midyear Clinical Meeting of the American Society of Health-


December 10, 2002 Rosuvastatin CE Program: Midyear Clinical Meeting of the American Society of Health-


January 24, 2002 Atrial Arrhythmia Update 2002.

Part of the Critical Care and Infectious Disease Pharmacotherapy

Symposium.

CE Program: Hospital Pharmacists: Dearborn, MI.

January 31, 2002 Statin Induced Muscle Toxicity: Impact of Pharmacology and

Pharmacokinetics.

Medical Grand Rounds: Phelps Memorial Hospital, NY

May 15, 2003 Drug-Drug Interactions: The Heart of the Matter

Medical Grand Rounds: Middlesex Hospital, Middlesex, CT

July 17, 2003 To Take or Not To Take: Herbs in Cardiovascular Disease.

Patient Education Seminar: Congestive Heart Failure Clinic Patients and Their

Families.

Hartford Hospital, Wethersfield Campus, Wethersfield, CT

October 16, 2003 Statin Induced Muscle Toxicity: Impact of Pharmacology and

Pharmacokinetics.

PharmaCE. CE Program: Community Pharmacists: LaGuardia Sheraton, Flushing,

NY

October 25, 2003 Clash of the Titans: A Comprehensive Review of HMG CoA RIs.

CME Program: Pharmacists, Physicians, Nurse Practitioners: Hartford Hospital

Department of Cardiology: Rocky Hill Marriott, Rocky Hill, CT.

November 11, 2003 Drug-Drug Interactions: The Heart of the Matter Medical Grand Rounds: Mercy Medical Center, Springfield, MA

November 12, 2003 Statin Induced Muscle Toxicity: Impact of Pharmacology and

Pharmacokinetics.

PharmaCE. CE Program: Community Pharmacists: Farmington Marriott,

Farmington, CT

November 12, 2003 Angiotensin Receptor Blockers: Around the World in 44 Minutes.

PharmaCE. CE Program: Community Pharmacists: Farmington Marriott,

Farmington, CT

November 18, 2003 The Rhythm is Gonna Get You! Research in Preventing and Treating

Arrhythmias.

Hewitt Pharmacy Research Symposium. University of Connecticut, Storrs, CT

November 29, 2003 State of the Art in Stable Angina Treatment.

Medical Grand Rounds: Stamford Medical Center: Stamford, CT

December 11, 2003 Critical Differences of Antiarrhythmic Agents.

CE Program: ASHP Midyear Clinical Meeting: New Orleans, LA.

January 20, 2004 Drug-Drug Interactions: The Heart of the Matter.

CE Program: CSHP Hospital Pharmacists Monthly Meeting: Rocky Hill, CT.

February 5, 2004 Advances in the Treatment of Hyperlipidemia.

CE Program: CPA Community Pharmacists: Annual Meeting: Southington, CT

February 19, 2004 Advancing into a New Era of Anticoagulant Therapy.

CE Program: Anticoagulation Pharmacists/Nurses/Physicians. Edison, NJ

March 11, 2004 Advancing into a New Era of Anticoagulant Therapy.

CE Program: Pharmacists/Nurses/Physicians. Hartford, CT

March 16, 2004 Advancing into a New Era of Anticoagulant Therapy.

CE Program: Pharmacists/Nurses/Physicians. Newburgh, NY

March 29, 2004 HMG CoA RI: Critical Safety Differences.

Physicians: Baystate Medical Center. Springfield, MA.

May 13, 2004 New Anticoagulants For Cardiac and Vascular Disorders.

CE Program: Third Annual Henry Low Heart Center Nursing Symposium.

Hartford, CT

June 21, 2004 Oral Anticoagulants: A Review of Current and Future Treatments.

CE Program. ASHP Annual Meeting, Las Vegas, NV.

July 27, 2004 Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.

CE Program, Pharmacists. Hackensack University Medical Center, Hackensack,

NJ

July 27, 2004 Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.

CE Program, Physicians, Nurse Practitioners. Saint Joseph’s Hospital,

Hackensack, NJ

August 14, 2004 Angiotensin Receptor Blockers: Around the World in 44 Minutes.

CE Program: Philippine-American Physicians/ Northeast Chapter Annual Meeting.

Foxwoods, CT.

September 14, 2004 Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.

CE Program, Physicians, Pharmacists: Federal Healthcare/Dept of Defense

Lecture Series. Washington, DC. September 17, 2004 Women and Cardiac Disease.

CE Program, Pharmacists, Connecticut Pharmacists Association. Rocky Hill, CT

September 30, 2004 Impact of ARBs on Renal Function in Type 2 Diabetics.

CE Program, Physicians, Nurses: Healthwise Medical Associates, Vernon, CT.

October 1, 2004 Oral Anticoagulants: A Review of Current and Future Treatments CE Program. CSHP Catch the Wave Meeting. Farmington, CT

October 15, 2004 Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.

CE Program, Physicians, Pharmacists: Newark, NJ

November 2, 2004 Pharmacotherapy of Hypertension.

CE Program, Pharmacists, PharmEd. Rocky Hill, CT

December 7, 2004 Critical Differences of ARBs.

CE Program. Pharmacists: ASHP Midyear Clinical Meeting. Orlando, FL.

December 15, 2004 Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.

Dinner Program. Physicians. Poughkeepsie, NY.

May 17, 2005 Hypertension: Epidemiology, Pathophysiology and Pharmacotherapy.

Noontime Conference: Pioneer Valley Cardiologists.

May 18, 2005 Moderator: Critical Differences Between Cardiac Drugs.

CE Program. Pharmacists. Schwarting Symposium. University of Connecticut.

Storrs, CT.

May 18, 2005 Antiarrhythmic Drug Therapy.

CE Program. Pharmacists. Schwarting Symposium. University of Connecticut.

Storrs, CT.

June 15, 2005 HMG CoA RI Therapy for Hyperlipidemia.

Dinner Program, Physicians & Nurse Practitioners, Providence, RI.

September 16, 2005 Statins: Efficacy and Muscle Safety Comparisons.

CE Program: Pharmacists. Eugene Applebaum College of Pharmacy. Detroit, MI

December 6, 2005 Non-Pharmacologic Therapies for Atrial Fibrillation & Flutter.

CE Program: Pharmacists: ASHP Midyear Clinical Meeting. Las Vegas, NV.

December 28, 2005 Advanced Technology for Cardiac Care.

CE Program: Pharmacists: CE Finale, University of Connecticut, Storrs, CT

March 21, 2006 New Frontiers, The Use of Inhaled Insulin for Diabetes Mellitus.

CE Program: Pharmacists: CSHP Monthly Meeting: Manor Inn, Milldale, CT

November 8, 2006 Efficacy and Safety Implications of Intensive Lipid Lowering.

Physicians (Attendings, Fellows), Nurse Practitioners. St Vincent Hospital,

Worcester, MA.

December 2, 2006 Radiofrequency Ablation Therapy: Use of Anticoagulation.

CE Program, Pharmacists. 21st Annual Pharmacy Invitational Conference on

Antithrombotic Therapy, Anaheim, CA.

December 27, 2006 New Frontiers in Herbal Pharmacotherapy & Research.

CE Program, CE Finale. University of Connecticut, Storrs, CT.

March 10, 2007 Safety and Efficacy Implications of Statin Therapy.

CE Program, Pharmacy Practice Institute, Albany College of Pharmacy, Albany

Marriott, Albany, NY.

March 13, 2007 Treatment of Myocardial Infarction: PICCs Format

CE Program. Connecticut Society of Health-System’s Pharmacists, Rocky Hill, CT

April 18, 2007 Acute Ischemic Stroke

CE Program. Connecticut Pharmacists Association, Trumbull, CT

September 19, 2007 Keynote Address: Antiarrhythmic Drug Prophylaxis in the Open Heart

Surgery Patient: Cost Effectiveness and Quality Issues.

Twentieth Annual Heartbeats Symposia: The Forum Conference and Education

Center, Cleveland, Ohio. [Note: The only Non-Physician Invited as Speaker]

Research Evaluating my Teaching

Section H




In 2006 I developed a new approach to teach case based information called Pharmacist

Interactive Clinical Cases. This approach was designed to be more interactive, clinically

relevant, and fun to complete. I piloted the cases on experiential rotation students and

gathered data on their perceptions via a survey tool. I used it in Therapeutics 254 in

Spring 2007 and also administered a survey asking for student perceptions. Students in

both surveys rated the PICCs surveys much higher than traditional case based learning

approaches. The manuscript summarizing these findings is given in the following

attachment.

Book Chapters and Review Articles of Note

Section I C. Michael White, Pharm.D., FCP, FCCP



Book chapters and review articles are important teaching modalities for pharmacists and

students. By summarizing the current literature and presenting in a way that empowers

and engages the reader, effective distance learning occurs. Of particular note, I have co-

authored book chapters in Applied Therapeutics and the Pharmacotherapy Self-

Assessment Program which are high visibility and high impact books. Several of my

review articles in the Annals of Pharmacotherapy or US Pharmacist have been given

accompanying CE questions.

NON-RESEARCH

PUBLICATIONS

BOOK CHAPTERS

(15 Published/In Press. 1 in Progress)

February 2001 Chow MSS, White CM. Cardiac Arrhythmias, Chapter 18. In: Koda-Kimble

MA, Young LY (Eds). Applied Therapeutics: The Clinical Use of Drugs. 7th Edition.

Lippincott Williams & Wilkins, Philadelphia, PA. 2001: pg 18.1-18.36.

April 2002 Chow MSS, White CM. Cardiac Arrhythmias, Chapter 17. In: Koda-Kimble

MA, Young LY (Eds). Handbook of Applied Therapeutics. 7th Edition. Lippincott

Williams & Wilkins Philadelphia, PA 2001: pg 17.1-17.16.

August 2002 White CM. Cardiac Arrhythmias, Chapter 5. In: Jeffrey S (Ed). Geriatric

Pharmacy Certification Program Review Coursebook, 3rd

Edition. American Society

of Consultant Pharmacists, Alexandria, VA. Accessed at

GeriatricPharmacyReview.com.

January 2004 White CM, McBride B, Kalus J. Dyslipidemias, Chapter 2. In: Schumock GT,

Brungage DM, et al (Eds). Pharmacotherapy Self Assessment Program, Fifth

Edition, Book 1 Cardiology. American College of Clinical Pharmacy Inc, Kansas

City. MO. 2004: pg 165-190.

August 2004 White CM, Song J, Chow MSS. Cardiac Arrhythmias, Chapter 20. In: Koda-

Kimble MA, Young LY (Eds). Applied Therapeutics: The Clinical Use of Drugs. 8th

Edition. Lippincott Williams & Wilkins, NY, NY. 2004; Pg 20.1-20.33.

April 2005 Caron M, White CM. Fundamental Concepts in Pharmacokinetics and

Pharmacodynamics of Fibrinolytic Agents. In: Becker RC, Harrington RA (Eds).

Clinical, Interventional, and Investigational Thrombocardiology. Marcell Dekker,

Inc, New York, NY. 2005

April 2005 Caron M, Kalus J, McBride B, White CM. Fundamental Concepts in

Pharmacokinetics and Pharmacodynamics of Antithrombotic Agents. In: Becker

RC, Harrington RA (Eds). Clinical, Interventional, and Investigational

Thrombocardiology Marcell Dekker, Inc, New York, NY. 2005

April 2005 White CM, Song J, Chow MSS. Cardiac Arrhythmias, Chapter 20. In: Koda-

Kimble MA, Young LY (Eds). Handbook of Applied Therapeutics. 8th Edition.

Lippincott Williams & Wilkins, NY, NY. 2005; Pg 20.1-20.15.

June 2005 White CM. Cardiac Arrhythmias, Chapter 5. In: Jeffrey S (Ed). Geriatric

Pharmacy Certification Program Review Coursebook, 4th Edition. American Society

of Consultant Pharmacists, Alexandria, VA. Accessed at

GeriatricPharmacyReview.com.

August 2005 White CM, McBride BF, Kalus J. Dyslipidemia Algorithms. In: Kishi W. A

Guide to Clinical Decision-Making: The PSAP Algorithms, Third Edition.

American College of Clinical Pharmacy Inc, Kansas City, MO 2005.

April 2006 White CM. Careers in Pharmacy. In: Castagno JM. (Ed). Lands and Peoples: The

New Book of Popular Science. Scholastic Library Publishing, Danbury, CT. pg 462-

64.

April 2006 Davis G, White CM. Medications and Drugs. In: Castagno JM. (Ed). Lands and

Peoples: The New Book of Popular Science. Scholastic Library Publishing, Danbury,

CT. 2006: pg 460-7.

April 2006 Rhines K, White CM. Drug Delivery Technology. In: Castagno JM. (Ed). Lands

and Peoples: The New Book of Popular Science. Scholastic Library Publishing,

Danbury, CT. 2006: pg 468-75.

January 2007 White CM, Coleman CI. Drug Induced Cardiac Diseases. In: Schumock GT,

Brungage DM, et al (Eds). Pharmacotherapy Self Assessment Program, Sixth

Edition, Book 1 Cardiology. American College of Clinical Pharmacy Inc, Kansas

City. MO. 2007: 39-56.

In Press White CM, Song J, Kluger J. Research Considerations in Cardiovascular

Therapeutic Areas. Chapter 11. In: Even RP, Smith LJ (Eds). Drug & Biologic

Development. Springer Verlag, Inc., New York, NY.

In Progress White CM, Song J, Kalus J. Cardiac Arrhythmias, Chapter __. In: Koda-Kimble

MA, Young LY (Eds). Applied Therapeutics: The Clinical Use of Drugs. 9th Edition.

Lippincott Williams & Wilkins, NY, NY. 2007 pg __ to __.

White CM, Song J, Chow MSS. Cardiac Arrhythmias, Chapter __. In: Koda-

Kimble MA, Young LY (Eds). Handbook of Applied Therapeutics. 9th Edition.

Lippincott Williams & Wilkins, NY, NY. 2008; Pg __- __.

BOOKS (1 Published)

June 2001 White CM, Dunn A, Reddy P. Angina Pectoris Disease State Management

Module. University of Kentucky College of Pharmacy, Lexington, KY. 2001.

REVIEW ARTICLES (72 Published or In Press)

July 1996 White CM. Treatment of Hypercholesterolemia

US Pharmacist 1996;21:76-90.

November 1996 White CM, Chow MS. Beyond ACE inhibition: The Role of Angiotensin II Type

1 Receptor Blockers in Cardiovascular Medicine.

Formulary 1996;31:1058-64.

December 1996 White CM. Drug Induced Respiratory Depression.


December 1996 Milch LM, White CM, Wolfe S. Focus of Fluticasone

Formulary 1996;31:1165-77.

February 1997 White CM. Weight Based Heparin Dosing Versus Standard Dosing

Connecticut Medicine 1997;61:103-104.

March 1997 White CM, Chow MS. The Role of Positive Inotropic Agents in Severe Heart

Failure

Formulary 1997;32:255-266.

April 1997 White CM, Chow MS. Future Pharmacotherapeutic Options in the Treatment

of Heart Failure


September 1997 White CM. The Use of Aspirin for the Prevention and Treatment of Coronary

Artery Disease


October 1997 White CM. The Role of Calcium Channel Blockers in Congestive Heart Failure Connecticut Medicine 1997;61:669-71.

November 1997 White CM, Chow MS. Reassessing the Risks of Calcium Channel Blockers In

Medicine

Formulary 1997;32:1146-65.

January 1998 White CM, Chow MS. A Review of HMG CoA Reductase Inhibitors US Pharmacist 1998;23:HS19-HS30.

March 1998 White CM, Chow MSS. Applying Principles of Chronotherapy to Drug Delivery

Systems and Dosage Times

Formulary 1998;33:208-220.

April 1998 White CM. Catecholamines and Their Blockade in Heart Failure American Journal of Health-Systems Pharmacists 1998;55:676-682.

June 1998 White CM. A Review of the Pharmacologic, Pharmacokinetic, and Therapeutic

Differences Between ACE Inhibitors

Pharmacotherapy 1998;18:588-599.

February 1999 White CM. Pharmacological Effects of HMG CoA Reductase Inhibitors Other

Than Lipoprotein Modulation Journal of Clinical Pharmacology 1999;39:111-8.

May 1999 White CM. Cardiovascular Effects, Pharmacokinetics, and Side Effects of

Intravenous Glucagon Administration.

Journal of Clinical Pharmacology 1999;39:442-7.

June 1999 White CM, Dicks RS. Focus on Rivastigmine: An Acetylcholinesterase Inhibitor

for Patients with Alzheimer’s Disease. Formulary 1999;34:493-9.

October 1999 White CM. Prevention of Sub-Optimal Beta-Blocker Treatment in Patients with

Myocardial Infarctions.

Annals of Pharmacotherapy 1999;33:1063-72.

December 1999 Song J, White CM.* Beta-Adrenoceptor Blockers in Heart Failure.


* = Corresponding Author

January 2000 Tsikouris JP, White CM,* Kluger J. Optimizing Oral Dosing and Monitoring of

Noncardiac Toxicities with Chronic Amiodarone Therapy.



February 2000 Song J, White CM.* Pharmacologic, Pharmacokinetic, and Therapeutic

Differences Among Angiotensin II Receptor Antagonists.



February 2000 White CM, Tsikouris J. A Review of the Pathophysiology and

Pharmacotherapy of Vasovagal Syncope.


April 2000 White CM. An Evaluation of CYP 3A4 Drug Interactions with HMG CoA

Reductase Inhibitors.

Formulary 2000;35:343-52.

August 2000 Tsikouris J, White CM.* Focus on Tenectaplase.

Formulary 2000;35:647-53.


September 2000 White CM. A Pharmacokinetic Comparison of HMG CoA Reductase

Inhibitors.


October 2000 White CM. ACE Inhibition in Patients Following Myocardial Infarction or

With Heart Failure.

American Journal of Health-System Pharmacists 2000;57(Suppl):s18-s25.

October 2000 Song J, White CM.* Tykosyn ® (Dofetilide).



February 2001 Song JC, White CM.* Do HMG CoA Reductase Inhibitors Affect

Fibrinogen? Annals of Pharmacotherapy 2001;35:236-41.


March 2001 Caron M, White CM.* Intravenous Amiodarone For Cardiac Arrest. Connecticut Medicine 2001;65:81-2.


April 2001 Caron M, White CM.* An Evaluation of the Antihypercholesterolemic Effects

of Herbal Products



June 2001 Markelon J, Caron M, Song J, White CM.* Tips for Safely Withdrawing Other

Antiarrhythmics Before Initiating Dofetilide.

Formulary 2001;36:471.


July 2001 Song J, White CM.* Focus on Olmesartan Medoxomil (Cs-866): An Angiotensin

Receptor Blocker for Treatment of Hypertension.

Formulary 2001;36:487-99.


September 2001 Caron M, White CM.* Focus on Nesiritide – An Update.

Formulary 2001;36:639-43.


October 2001 Caron M, Kluger J, White CM.* Amiodarone in the New AHA Guidelines for

Ventricular Tachyarrhythmias.



October 2001 Song J, White CM.* Focus on Omapatrilat.

Formulary 2001;36:698-707.


October 2001 Kalus J, White CM.* A Comprehensive Review of Antihypertensive Agents

Providing Renal Protection.



November 2001 Caron M, Kuti J, Quintilliani R, White CM.* Focus on Drotrecogin Alpha

(Activated): A New Approach to Treating Sepsis.

Formulary 2001;36:784-95.


April 2002 Song J, White CM.* Clinical Pharmacokinetics and Selective

Pharmacodynamics of Newer ACE Inhibitors: An Update.

Clinical Pharmacokinetics 2002;41:207-24.


May 2002 Kalus J, White CM.* Focus on Lercanidipine: a Long-Acting Dihydropyridine

Calcium Channel Blocker.

Formulary 2002;37:234-8.


August 2002 White CM. Do Atypical Antipsychotics Increase the QTc Interval?


September 2002 White CM. Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin.


September 2002 Coleman C, Reddy P, White CM. Budesonide: It’s Role in Chrohn’s Disease

Therapy. Connecticut Medicine 2002;66:523-6.

October 2002 Coleman C, Reddy P, Song J, White CM.* Focus on Eplerenone: The First

Selective Aldosterone Receptor Antagonist for the Treatment of Hypertension.

Formulary 2002;37:514-24.


November 2002 Kalus J, White CM.* A Comparison of Amlodipine to Angiotensin II Type-1

Receptor Blockers for Non-Hypertension Indications.

Annals of Pharmacotherapy, 2002;36:1759-66.


November 2002 White CM. HMG CoA Reductase Inhibitor Induced Muscle Toxicity: Risks,

Monitoring, and Management.

Formulary 2002;37:583-93.

December 2002 Kalus J, White CM.* Monitoring Anti-factor Xa Activity of the Low-Molecular-

Weight Heparins in the Clinical Setting: Who, Why, How, and When?



May 2003 White CM. Venlafaxine in EP Procedure? Clinical Case Review Featured in Clinical Twisters Segment.

Drug Topics 2003;147:HSE11.

August 2003 McBride B, White CM.* Acute Decompensated Heart Failure: A

Comtemporary Approach to Pharmacotherapeutic Management.

Pharmacotherapy 2003;997-1020.


August 2003 McBride BF, White CM.* Ranolazine: A Novel Metabolic Modulator for the

Treatment of Chronic Stable Angina.

Formulary 2003;38:461-6.


August 2003 Perkerson K, Coleman CI, White CM. Aldosterone Receptor Antagonists in the

Treatment of Heart Failure. Connecticut Medicine 2003;67:397-400.

September 2003 McBride B, White CM.* Levosimendan: Implications for Clinicians.



November 2003 McBride B, White CM.* Are There Ethnic Differences in Heart Failure

Medication Response?


* = Denotes Corresponding Author

February 2004 Cheng JW, Frank L, Garrett SD, Lu Y, Sanoski CA, White CM. Key Articles

and Guidelines in Pharmaceutical Management of Arrhythmia.

Pharmacotherapy 2004;24:248-279

March 2004 Min B, White CM.* Hawthorn. Connecticut Medicine 2004;68:161-4.


June 2004 Kluger J, White CM. Amiodarone Prevents Symptomatic Atrial Fibrillation

and Reduces the Risk of Cerebrovascular Accidents and Ventricular

Tachycardia after Open Heart Surgery: Results of the Atrial Fibrillation

Suppression Trial (AFIST).

Cardiac Electrophysiology Review 2003;7:165-7.

June 2004 McBride B, White CM.* Anemia Management in Heart Failure: A Thick

Review of Thin Data.



August 2004 Gillespie E, Perkerson K, White CM, Coleman CI. Possible Impact of Aprotinin

on Post-Cardiothoracic Surgery Atrial Fibrillation.


August 2004 Sander S, White CM.* Focus on Ximelagatran: A New Oral Anticoagulant.

Formulary 2004;39:398-404.


September 2004 Coleman CI, Linberg M, Perkerson K, White CM.* Focus on:

Simvastatin/Ezetimibe.

Formulary 2004;39:437-44.


October 2004 Coyle J, Gardner S, White CM.* Angiotensin Receptor Blockers in

Hypertensive Patients With Type II Diabetes Mellitus.



Featured Article with CE Questions and Credits.

November 2004 Henyon N, White CM.* Adjunctive Intravenous Magnesium to Reduce Toxicity

and Enhance Efficacy of Class III Antiarrhythmic Agents.



December 2004 White CM. Thrombin Directed Inhibitors: Pharmacology and Clinical Use.

American Heart Journal 2004;149:s54-s60.

January 2005 McBride BF, White CM.* Critical Differences Among Beta-Adrenoceptor

Antagonists in Heart Failure: Debating the MERIT of COMET.

J Clin Pharmacol 2005;45:6-24.


February 2005 Sander S, White CM.* The Use of Prophylactic Amiodarone After

Cardiothoracic Surgery Reduces the Incidence of Atrial Fibrillation



June 2005 Henyon N, White CM.* Focus on Ranolazine: An Update.

Formulary 2005;40:323-328.


December 2005 Patel AA, White CM, Coleman CI. Focus on Exubra, an Inhaled Insulin.

Formulary 2005;40:429-36.

June 2006 ASHP Commission on Therapeutics. ASHP Therapeutic Position Statement on

the Treatment of Hypertension.

Am J Health Sys Pharm 2006;63:1074-80.

August 2006 Dale K, White CM.* The Use of Intravenous Amiodarone for Chemical

Conversion of Atrial Fibrillation.

Connecticut Medicine 2006; 70:433-8.


November 2006 Shah S, White CM.* Focus on Rimonabant: A Novel CB1 Receptor Antagonist

for the Treatment of Obesity.

Formulary 2006;41:561-9.


February 2007 Patel AA, White CM, Coleman CI. Protamine to Rapidly Reduce Anticoagulant

Effect of Heparin in Percutaneous Coronary Intervention.


March 2007 Baker W, White CM.* Post-Cardiothoracic Atrial Fibrillation: A Review of

Preventive Strategies.

Ann Pharmacother 2007;41: DOI 10.1345/aph.1H594


April 2007 Baker WL, White CM.* Renin-Angiotensin System Inhibitors for Prevention of

New Onset Atrial Fibrillation.



April 2007 Dale K, White CM.* Dronedarone: An Amiodarone Analog for the Treatment

of Atrial Fibrillation and Atrial Flutter.

Ann Pharmacother 2007;41:DOI 10.1345/aph.1H524.


May 2007 Reinhart K, White CM.* Focus on Sitaxsentan.

Formulary 2007;42:295-301.


Shah, S, Kluger, J, White CM.* Dual Antiarrhythmic Therapy.

Pharmacotherapy, In Press.


Sanoski C, Cheng JW, Kalus JS, White CM. Key Articles and Guidelines in

Pharmaceutical Management of Arrhythmia.

Pharmacotherapy, In Press

Editorials (n=2)

January 2006 White CM. Should all Patients Receive Prophylactic Amiodarone Therapy

Before Cardiac Surgery?

Nature, Clinical Practice: Cardiovascular Medicine. 2006;3:18-9.

December 2006 White CM. Assuring Patients Receive Medications Proven to Help Them Live

Longer: A Pharmacists Call to Arms.


Summary of Review Article/Editorial Publications (n=74)

22= Formulary (Impact Factor 0.220)

20 = Connecticut Medicine (Impact Factor Unknown)

8 = Annals of Pharmacotherapy (Impact Factor 1.822)

7 = Pharmacotherapy (Impact Factor 2.002)

5 = Journal of Clinical Pharmacology (Impact Factor 1.945)

5 = US Pharmacist (Impact Factor Unknown)

3 = American Journal of Health-System Pharmacists (Impact Factor 1.44)

1 = Clinical Pharmacokinetics (Impact Factor 3.899)

1 = American Heart Journal (Impact Factor 3.300)

1 = Nature, Clinical Practice: Cardiovascular Medicine (Impact Factor Unknown)

1 = Cardiac Electrophysiology Review (Impact Factor Unknown)

1 = Drug Topics (Impact Factor Unknown)

Teaching Portfolio


Professor

Department of Pharmacy Practice


Teaching Philosophy and Approach - University of … Hartford Hospital Department of Pharmacy Core...

Documents

Transcript of Teaching Philosophy and Approach - University of … Hartford Hospital Department of Pharmacy Core...